Pharma group Lupin joins India's push into biosimilar drugs - (Nikkei Asian Review via NewsPoints Desk)

  • Lupin has become the latest Indian firm to enter the biosimilar space, Nikkei Asian Review reported Thursday.

  • Lupin president Cyrus Karkaria said the company plans to diversify business by launching biosimilars slated in Japan, Europe and other markets by the end of the year.

  • The global biosimilar market is currently dominated by major firms such as Amgen, Novartis and Pfizer as well as Celltrion.

  • "What's very evident is that for small-molecule [drugs], the [discovery] cycle is actually running out," Karkaria stated.

  • McKinsey estimated that biosimilar revenue could triple to $15 billion by next year.

  • "What [Lupin] is also trying to do now is to build niche products that have fewer potential competitors," explained HDFC Securities analyst Amey Chalke.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles